Ropes & Gray advised Kailera Therapeutics, Inc. on the transaction. Kailera Therapeutics, Inc. (“Kailera”) announced raising $400 million in Series A financing. Kailera announced its launch...
You must be a Standard 1 Year member to access this content.
Ashurst acted as the U.S. counsel to Shanghai Voicecomm Information Technology, while O’Melveny represented the underwriters on the offering. Shanghai Voicecomm Information Technology Co., Ltd. (2495.HK)...
You must be a Standard 1 Year member to access this content.
On the deal, O’Melveny acted for Laopu Gold, Linklaters advised the underwriters. Laopu Gold Co., Ltd. completed the global offering and listing of H shares on...
You must be a Standard 1 Year member to access this content.
Skadden is advising Edwards Lifesciences, while Ropes & Gray is providing legal counsel to BD on the deal. Edwards Lifesciences has entered into a definitive agreement...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Takeda Pharmaceuticals on the deal. Takeda Pharmaceuticals announced it has entered into a collaboration and exclusive license agreement with Degron Therapeutics (“Degron”)...
You must be a Standard 1 Year member to access this content.
O’Melveny represented China International Capital Corporation Hong Kong Securities Limited as the sole sponsor and overall coordinator in the IPO. Qyuns Therapeutics Co., Ltd. (2509.HK) announced...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Allorion Therapeutics on the transaction. Allorion Therapeutics (Allorion) announced it entered into a global licensing agreement with Avenzo Therapeutics Inc. (Avenzo) to develop and...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented LianBio on the deal. LianBio (Nasdaq: LIAN) announced it has entered into an agreement with Bristol Myers Squibb (NYSE:BMY)(BMS), whereby BMS has obtained...
You must be a Standard 1 Year member to access this content.
O’Melveny represented the sole sponsor, the coordinators and the underwriters in the transaction. Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) announced its initial public offering and listing...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented HUTCHMED on the deal. HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited announced an exclusive worldwide license agreement with Japan’s largest drugmaker Takeda...
You must be a Standard 1 Year member to access this content.
O’Melveny advised Beauty Farm. Clifford Chance has advised the joint sponsors. Shearman & Sterling advised Beijing Xinyu Meiye Holdings Limited as a selling shareholder. Beauty Farm...
You must be a Standard 1 Year member to access this content.
Herbert Smith Freehills advised CICC and CSCI on the deal while O’Melveny recently represented 3D Medicines. CICC and CSCI acted as joint sponsors of 3D Medicines...
You must be a Standard 1 Year member to access this content.
